YT 146 | CAS#90596-75-1| MedKoo

MedKoo Cat#: 341265 | Name: YT 146

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YT 146 is a biochemical.

Chemical Structure

YT 146

CAS#90596-75-1

Theoretical Analysis

MedKoo Cat#: 341265

Name: YT 146

CAS#: 90596-75-1

Chemical Formula: C18H25N5O4

Exact Mass: 375.1907

Molecular Weight: 375.43

Elemental Analysis: C, 57.59; H, 6.71; N, 18.65; O, 17.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

YT 146; YT-146; YT146.

IUPAC/Chemical Name

Adenosine, 2-(1-octynyl)-

InChi Key

NVGGIHKSKVAPEY-XKLVTHTNSA-N

InChi Code

InChI=1S/C18H25N5O4/c1-2-3-4-5-6-7-8-12-21-16(19)13-17(22-12)23(10-20-13)18-15(26)14(25)11(9-24)27-18/h10-11,14-15,18,24-26H,2-6,9H2,1H3,(H2,19,21,22)/t11-,14-,15-,18-/m1/s1

SMILES Code

OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N=C(C#CCCCCCC)N=C32)N)O1)O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 375.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sasamori J, Abe Y, Marunouchi T, Manome Y, Uchibori T, Tanonaka K. Effects of 2-Octynyladenosine (YT-146) on Mitochondrial Function in Ischemic/Reperfused Rat Hearts. Biol Pharm Bull. 2015;38(12):1946-53. doi: 10.1248/bpb.b15-00629. PubMed PMID: 26632185. 2: Sasamori J, Aihara K, Uchibori T, Takahashi A, Takeo S, Tanonaka K. Cardioprotective effects of 2-octynyladenosine (YT-146) in ischemic/reperfused rat hearts. J Cardiovasc Pharmacol. 2011 Feb;57(2):166-73. doi: 10.1097/FJC.0b013e318201c264. PubMed PMID: 21052018. 3: Sasamori J, Aihara K, Yoneyama F, Sato I, Kogi K, Takeo S. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146). J Cardiovasc Pharmacol. 2006 Apr;47(4):614-20. PubMed PMID: 16680077. 4: Konno T, Murakami A, Uchibori T, Nagai A, Kogi K, Nakahata N. Involvement of adenosine A2a receptor in intraocular pressure decrease induced by 2-(1-octyn-1-yl)adenosine or 2-(6-cyano-1-hexyn-1-yl)adenosine. J Pharmacol Sci. 2005 Apr;97(4):501-9. Epub 2005 Apr 9. PubMed PMID: 15821340. 5: Harada N, Okajima K, Murakami K, Usune S, Sato C, Ohshima K, Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther. 2000 Sep;294(3):1034-42. PubMed PMID: 10945856. 6: Harada N, Okajima K, Katsuragi T. [Adenosine reduces ischemia/reperfusion-induced liver injury by inhibiting leukocyte activation]. Nihon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:159P-167P. Japanese. PubMed PMID: 10629874. 7: Yoneyama F, Aihara K, Kogi K, Satoh K, Taira N. Similarity and dissimilarity in mode and mechanism of action between YT-146, a selective adenosine receptor A2 agonist, and adenosine in isolated canine hearts. Tohoku J Exp Med. 1999 May;188(1):31-45. PubMed PMID: 10494898. 8: Ono T, Matsuoka I, Ohkubo S, Kimura J, Nakanishi H. Effects of YT-146 [2-(1-octynyl) adenosine], an adenosine A2A receptor agonist, on cAMP production and noradrenaline release in PC12 cells. Jpn J Pharmacol. 1998 Nov;78(3):269-77. PubMed PMID: 9869260. 9: Tanaka M, Takeda K, Takesako T, Takenaka K, Itoh H, Nakata T, Sasaki S, Nakagawa M. Altered cardiovascular responses to purinergic A2 stimulation in the nucleus tractus solitarius of spontaneously hypertensive rats. J Hypertens. 1995 Nov;13(11):1285-90. PubMed PMID: 8984126. 10: Takiguchi Y, Nagano M, Ikeda Y, Nakashima M. Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Eur J Pharmacol. 1995 Aug 4;281(2):205-7. PubMed PMID: 7589208. 11: Abiru T, Endo K, Machida H. Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A2 receptor agonist, in the isolated rat femoral artery and vein. Eur J Pharmacol. 1995 Jul 25;281(1):9-15. PubMed PMID: 8566123. 12: Iwamoto T, Umemura S, Toya Y, Hirawa N, Takeda K, Kihara M, Ishii M. Antihypertensive effects of 2-octynyladenosine (YT-146), a selective adenosine A2 receptor agonist, in Dahl salt-sensitive rats. Am J Hypertens. 1994 Nov;7(11):984-8. PubMed PMID: 7848625. 13: Makujina SR, Olanrewaju HA, Mustafa SJ. Evidence against KATP channel involvement in adenosine receptor-mediated dilation of epicardial vessels. Am J Physiol. 1994 Aug;267(2 Pt 2):H716-24. PubMed PMID: 8067427. 14: Iwamoto T, Umemura S, Toya Y, Uchibori T, Kogi K, Takagi N, Ishii M. Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10. PubMed PMID: 8135838. 15: Furukawa S, Satoh K, Taira N. Opening of ATP-sensitive K+ channels responsible for adenosine A2 receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein. Eur J Pharmacol. 1993 May 19;236(2):255-62. PubMed PMID: 8319753. 16: Yoneyama F, Yamada H, Satoh K, Taira N. Vasodepressor mechanisms of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A2 receptor agonist, involve the opening of glibenclamide-sensitive K+ channels. Eur J Pharmacol. 1992 Mar 24;213(2):199-204. PubMed PMID: 1521559. 17: Kogi K, Uchibori T, Aihara K, Yamaguchi T, Abiru T. Pharmacological profile of the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146) in the cardiovascular system. Jpn J Pharmacol. 1991 Oct;57(2):153-65. PubMed PMID: 1812297. 18: Abiru T, Yamaguchi T, Watanabe Y, Kogi K, Aihara K, Matsuda A. The antihypertensive effect of 2-alkynyladenosines and their selective affinity for adenosine A2 receptors. Eur J Pharmacol. 1991 Apr 10;196(1):69-76. PubMed PMID: 1874281.